Cedars-Sinai Health System

A large retrospective study of over 161,000 cancer patients across four major U.S. health systems found that COVID-19 booster vaccines reduced hospitalizations and ICU admissions by 29%.

The Syn-One Test successfully detected phosphorylated alpha-synuclein in skin biopsies of 75% of patients with idiopathic REM sleep behavior disorder, closely mirroring the 73.5% conversion rate to neurodegenerative diseases within 12 years.

• Redesign Health and Cedars-Sinai have announced a strategic partnership committed to co-building multiple healthcare companies in the coming years, combining venture-building expertise with clinical excellence. • The collaboration aims to address critical U.S. healthcare challenges including rising costs, workforce shortages, and increasing complexity in patient care through clinically effective and operationally scalable solutions. • Healthcare entrepreneurs will gain access to Redesign Health's venture-building methodology that has launched over 60 companies and Cedars-Sinai's clinical expertise, operational infrastructure, and robust datasets for AI validation.

New research comparing randomized controlled trials and real-world outcomes for prostate cancer treatments shows clinical trials may slightly underestimate therapeutic benefits in actual practice.

The FDA has granted premarket approval to Element Science's Jewel Patch Wearable Cardioverter Defibrillator, designed to protect patients at temporary high risk for sudden cardiac arrest.

Post hoc analysis of the phase 3 EMBARK trial reveals over 80% of men with high-risk biochemically recurrent prostate cancer achieved full testosterone recovery after treatment suspension at 36 weeks.

A late-stage ALS patient treated with Trethera's investigational drug TRE-515 under FDA's Expanded Access program showed disease stabilization over three months, with improvements in vital capacity and functional rating scales.

• Cedars-Sinai and Oxford Science Enterprises have formed a strategic partnership to accelerate UK health tech startups' expansion into the US market through co-investment initiatives. • The partnership's first joint investment of $2 million supports Neu Health, a London-based startup developing an AI-powered smartphone platform for monitoring Parkinson's disease and dementia patients. • A six-month pilot program at Cedars-Sinai will validate Neu Health's platform with 150 neurology patients, marking a crucial step toward US market entry.

Cedars-Sinai study reveals traditional recruitment strategies are ineffective in engaging Black and Hispanic communities in clinical trials.

Researchers have developed an AI model, BB-TEN, that automates cancer staging using pathology reports, significantly reducing the time required for clinical trial candidate selection.